Improve Drug Project Success by Understanding Drug Target Safety Join Professor Ruth Roberts, Director and Co-founder, ApconiX Ltd, Dr Claire Sadler, Project Toxicologist, ApconiX and Dr Leigh Ann Burns Nass, President/Owner, Magnolia Toxicology Consulting, LLC in a live webinar on Thursday, October 1, 2020 at 11am EDT (4pm BST/UK) In [...]
22nd Annual John Doull Symposium Professor Ruth Roberts is guest speaker at the 22nd Annual John Doull Toxicology Symposium. This event is taking place on the 29th of September at 9am CDT. The Symposium is part of the University of Kansas, School of Medicine, Pharmacology, Toxicology & Therapeutics' series of [...]
Join Dr Richard Knight at the Digital AMR Conference Join Dr Richard Knight, Co-founder and Director of ApconiX, Dr Peter Warn consultant at Magic Bullet Consulting, and Aleksander Danilovski, Chief Scientific Officer & Senior Vice President, Global R&D and Regulatory Affairs at Xelia at the 4th AMR Conference as [...]
Science-Driven Design of the Preclinical Strategy: Case by Case Join Professor Ruth Roberts for the next science webinar in the Alderley Park Science Seminar Series: Science-Driven Design of the Preclinical Strategy: Case by Case Tuesday, 11 August 2020 12:00 pm to 1:00 pm Ruth will present lessons learned from >20 years’ [...]
Discover the Power of Target Safety Assessments in a SOT EHS Webinar Professor Ruth Roberts, Dr Claire Sadler and Dr Leigh Ann Burns Nass present Target Safety Assessments: Knowledge is Power webinar in a SOT 2020 Exhibitor Hosted Session. Membership of SOT is not required. Registration for the webinar [...]
ApconiX Co-organises British Toxicology Society Meeting The meeting that ApconiX is co-organising the British Toxicology Society “Science-led Strategies for Success in Discovery and Development Toxicology” is being rearranged for a date later in 2020 - watch this space for updates! Sponsored by Lonza and AstraZeneca and co-organised by ApconiX, [...]
Drug-induced liver injury severity and toxicity (DILIst): binary classification of 1279 drugs by human hepatotoxicity Abstract: Drug-induced liver injury (DILI) is of significant concern to drug development and regulatory review because of the limited success with existing preclinical models. For developing alternative methods, a large drug list is needed [...]
Merry Christmas and a Happy New Year Team ApconiX had a fabulous time at their Christmas party - secret Santa brought tears of laughter and sorrow and the odd gasp! A few team members went incognito. Wishing everyone a lovely holiday and the very best for the coming year. [...]
Professor Ruth Roberts is Speaking at the American Association of Pharmaceutical Scientists Professor Ruth Roberts, Co-Founder and Director of ApconiX will be speaking at the American Association of Pharmaceutical Scientists (AAPS) on Monday 4th November at 9:00am in a session entitled "Next Generation Technologies in Preclinical Development” chaired by Dr Shraddha [...]
Acuity Target Safety Assessments: Knowledge is Power A thorough understanding of potential target-related effects is crucial to making the right choices in drug discovery. Experienced project toxicologists extract and interpret data from mouse knockouts, human gene mutations and known effects of modulators to determine the potential consequences of target inhibition or [...]
